Torrey Pines Investment Biotech Investor Pharmaceutical Drug Development Start-Ups HDAC-inhibitors CD20 CD16 conjugates CNS AVN 211 lymphoma gosogliptin quisinostat virio HIV HBV Altzheimer Schizophrenia drug formulations CRO pre-clinical clinical

TORREY PINES
INVESTMENT

News About Us Portfolio Team Contacts

Torrey Pines Investment Attends Inauguration of the German Center for Neurodegenerative Diseases (DZNE) in Bonn, Germany

Avelas Biosciences Appoints Alexey Vinogradov, Ph.D., to Board of Directors

Avelas Biosciences to Present at 29th Annual Roth Conference

Leap Therapeutics to Present at 2017 Barclays Global Healthcare Conference

Leap Therapeutics to Present Preclinical and Clinical Data at 2017 AACR Annual Meeting

Viriom Reports Positive Findings in 48 Week Study of Elsulfavirine as Compared to Efavirenz in Combination with TDF/FTC at CROI 2017

ChemDiv Announces Multi-Year Hit Identification Collaboration with Janssen

Viriom to Present Positive Clinical Findings for Elsulfavirine vs Efavirenz in Combination with TDF/FTC

ChemDiv Announces Key Milestones in Abbott Pharma Collaboration

Viriom Announces Collaboration with NIH on Zika and Other Major Viral Diseases

NewVac Reports Primary Endpoint Met in Phase II Clinical Trial of Quisinostat in Combination with Paclitaxel and Carboplatin in Platinum-Resistant Ovarian Cancer

Viriom Announces Appointment of New Scientific Advisory Board Member

ChemDiv, Torrey Pines Investment and DZNE Announce Research Collaboration

Leap Therapeutics and Macrocure Announce Definitive Merger Agreement

Avelas Biosciences Completes $20 Million Series C Financing

SatRx LLC Announces First Registration in Russia of SatRx® (gosogliptin), an Innovative Drug for Treatment of Type 2 Diabetes

BioIntegrator, LLC Announces the Second Market Registration of Nescler®, a First Generic of the Novartis MS Blockbuster Gilenya®

Viriom Announces Receipt of Funding from the Skolkovo Foundation, ChemRar and Torrey Pines Investment to Develop Elsulfavirine, a Novel Preventive and Long-acting Treatment of HIV/AIDS

Avelas Biosciences Announces Positive Interim Phase 1b Results and Advances to Dose Expansion Stage

The President of Tatarstan discussed cooperation with Torrey Pines Investment in the field of pharmaceuticals and novel agricultural products

Chromis Successfully Secures Seed Funding from Torrey Pines Investment

ChemDiv and Abbott expand collaboration to develop branded generic pharmaceuticals for high growth emerging markets

Tensha Therapeutics To Be Acquired By Roche

ChemDiv Announces Achievement of a Development Milestone in a Drug Discovery Collaboration With Janssen

BioIntegrator Announced Launch of Neskler® -- a Generic of Novartis MS Blockbuster Gilenya® in Emerging Markets

J.P. Morgan 34th Annual Healthcare Conference

Viriom presented the results of the safety and antiviral effect of its novel drug Elsulfavirine at the EACS-2015 conference in Barcelona

Avineuro LLC  advances its highly selective 5-HT6R antagonist program in Alzheimer Disease

TeaRx launches an innovative anticoagulant Tearexaban

Ron Demuth Interviewed for Nature Drug Discovery News Article

Avelas Biosciences Completes 7.4M Funding

T23 Announces Global License of SCRIPPS’ CD22 Siglec Oncoimmunological Platform for B-cell Tumors

Viriom is Expanding its Portfolio of Novel Antiviral Drugs

ChemRar HighTech Center is featured in Pharmaceutical Executive article “Russia’s Bet on Biopharma”

 

 

Current Portfolio
TPI and ChemRar

TORREY PINES
INVESTMENT

6605 Nancy Ridge Drive, Ste 207, San Diego CA 92121
T: (858) 724-0581   F: (858) 345-3761
News About Us Portfolio Team Contacts